Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 2/20 | 0.43 |
| ▸ | MAPK11 | Q15759 | 4/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.43 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.43 |
| ▸ | RAF1 | P04049 | 2/20 | 0.43 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.43 |
| ▸ | MAPK12 | P53778 | 2/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | MPO | P05164 | 1/20 | 0.40 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.39 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13041312 | 0.89 | GABRA1 (0.43) | KCNH2 | |
| SCHEMBL8554786 | 0.84 | HTR2A (0.47) | MAPK11MAPK14MAPK13RAF1MAPK9 | |
| Bromide SCHEMBL8556262 | 0.83 | HTR2A (0.47) | MAPK11MAPK14MAPK13RAF1MAPK9 | |
| SCHEMBL3730571 | 0.71 | DRD4 (0.48) | PTGS2MAPK11MAPK14KCNH2 | |
| SCHEMBL8188473 | 0.68 | ALDH1A1 (0.61) | PTGS2MAPK14 | |
| SCHEMBL15849937 | 0.68 | ALDH1A1 (0.47) | PTGS2MAPK14 | |
| SCHEMBL2937820 | 0.66 | HTR3A (0.66) | MPO | |
| SCHEMBL1707108 | 0.66 | HTR3A (0.66) | MPO | |
| SCHEMBL1828844 | 0.66 | HTR3A (0.66) | MPO | |
| SCHEMBL29764150 | 0.66 | PTGS2 (0.51) | PTGS2MAPK11MAPK14MAPK13MAPK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100280073-A1 | TRICYCLIC INHIBITORS OF HYDROXYSTEROID DEHYDROGENASES | AMGEN INC. (US) | 2010-11-04 | — | — | US | claimed |
| US-8765788-B2 | Tricyclic inhibitors of hydroxysteroid dehydrogenases | AMGEN INC. (US) | 2014-07-01 | — | — | US | disclosed |
| US-8765788-B2 | Tricyclic inhibitors of hydroxysteroid dehydrogenases | AMGEN INC. (US) | 2014-07-01 | — | — | US | disclosed |
| US-20100280073-A1 | TRICYCLIC INHIBITORS OF HYDROXYSTEROID DEHYDROGENASES | AMGEN INC. (US) | 2010-11-04 | — | — | US | disclosed |
| WO-2008156601-A1 | TRICYCLIC INHIBITORS OF HYDROXYSTEROID DEHYDROGENASES | AMGEN INC. (US) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100280073-A1 | TRICYCLIC INHIBITORS OF HYDROXYSTEROID DEHYDROGENASES | HSD11B1, HSD3B1, HSD17B1 | PTGS2 462/4885MAPK11 3180/4885MAPK14 3853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.